Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Friedman

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
IEEE ... International Conference on Rehabilitation Robotics : [Proceedings]|August 4, 2019
Performance Evaluation of EEG/EMG Fusion Methods for Motion ClassificationJacob Tryon, Evan Friedman, Ana Luisa Trejos
Journal of Diabetes Investigation|May 17, 2016
Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese menSaori Tsuchiya, Evan Friedman, Carol Addy, et al.
IEEE Transactions on Neural Systems and Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|September 2, 2024
Tremor Suppression Using Functional Electrical StimulationZahra Habibollahi, Yue Zhou, Mary E Jenkins, et al.
Clinical Pharmacology in Drug Development|October 22, 2021
Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil FumarateDeanne Jackson Rudd, Saijuan Zhang, Kerry L Fillgrove, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for RaltegravirRajesh Krishna, Matthew L Rizk, Patrick J Larson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancerPamela N Munster, Eric H Rubin, Simon Van Belle, et al.
Clinical and Translational Science|August 31, 2021
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIVRandolph P Matthews, Wendy Ankrom, Evan Friedman, et al.
The Lancet. HIV|January 9, 2020
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trialDirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
IEEE ... International Conference on Rehabilitation Robotics : [Proceedings]|August 4, 2019
Performance Evaluation of EEG/EMG Fusion Methods for Motion ClassificationJacob Tryon, Evan Friedman, Ana Luisa Trejos
Journal of Diabetes Investigation|May 17, 2016
Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese menSaori Tsuchiya, Evan Friedman, Carol Addy, et al.
IEEE Transactions on Neural Systems and Rehabilitation Engineering : a Publication of the IEEE Engineering in Medicine and Biology Society|September 2, 2024
Tremor Suppression Using Functional Electrical StimulationZahra Habibollahi, Yue Zhou, Mary E Jenkins, et al.
Clinical Pharmacology in Drug Development|October 22, 2021
Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil FumarateDeanne Jackson Rudd, Saijuan Zhang, Kerry L Fillgrove, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for RaltegravirRajesh Krishna, Matthew L Rizk, Patrick J Larson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancerPamela N Munster, Eric H Rubin, Simon Van Belle, et al.
Clinical and Translational Science|August 31, 2021
Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIVRandolph P Matthews, Wendy Ankrom, Evan Friedman, et al.
The Lancet. HIV|January 9, 2020
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trialDirk Schürmann, Deanne Jackson Rudd, Saijuan Zhang, et al.
Pageof 1